Clinical Trial Update: Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007) [Phase 2]

View source ↗

Summary

Phase 2 trial update for vaniprevir (MK7009) with peginterferon and ribavirin in Hepatitis C; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegylated interferon (pegylated interferon alfa)
• Ribavirin (ribavirin)
• vaniprevir (vaniprevir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2014-10-01